

Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV–HCV co-infected patients: final results of the Spanish BOC HIV–HCV Study



M. Laguno^a, M.A. Von Wichmann^b, E. Van den Eynde^c, J. Navarro^d, C. Cifuentes^e, J. Murillas^f, S. Veloso^g, M. Martínez-Rebollar^{a,*}, J.M. Guardiola^h, A. Jouⁱ, J.L. Gómez-Sirvent^j, M. Cervantes^k, J.A. Pineda^l, S. López-Calvo^m, A. Carreroⁿ, M.L. Montes^o, E. Deig^p, A. Tapiz^q, J.D. Ruiz-Mesa^r, A. Cruceta^a, E. de Lazzari^a, J. Mallolas^a

^a Hospital Clínic de Barcelona/IDIBAPS, Villarroel 170, Barcelona, Spain

^b Hospital Universitario de Donostia, Donostia, Spain

^c Hospital Universitari de Bellvitge, Bellvitge, Spain

^d Hospital Universitari Vall d'Hebrón, Barcelona, Spain

^e Hospital Son Llàtzer, Palma de Mallorca, Spain

^f Hospital Son Espases, Palma de Mallorca, Spain

^g Hospital Universitari Joan XXIII, Tarragona, Spain

^h Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

ⁱ Hospital Universitari Germans Trias i Pujol, Badalona, Spain

^j Hospital Universitario de Canarias, Tenerife, Spain

^k Corporació Sanitària Parc Taulí, Sabadell, Spain

^l Hospital Universitario de Valme, Seville, Spain

^m Hospital Universitario A Coruña, La Coruña, Spain

ⁿ Hospital Universitario Gregorio Marañón, Madrid, Spain

^o Hospital Universitario de La Paz, Madrid, Spain

^p Hospital de Granollers, Granollers, Spain

^q Fundació Althaia, Manresa, Spain

^r Hospital Regional, Malaga, Spain

ARTICLE INFO

Article history:

Received 13 July 2016

Received in revised form 13 October 2016

Accepted 25 October 2016

Corresponding Editor: Eskild Petersen, Aarhus, Denmark

Keywords:

PEG-IFN/RBV + BOC therapy

HIV–HCV experienced patients

HCV genotype 1

Re-treatment

SUMMARY

Introduction: Boceprevir (BOC) was one of the first oral inhibitors of hepatitis C virus (HCV) NS3 protease to be developed. This study assessed the safety and efficacy of BOC + pegylated interferon- α 2a/ribavirin (PEG-IFN/RBV) in the retreatment of HIV–HCV co-infected patients with HCV genotype 1.

Methods: This was a phase III prospective trial. HIV–HCV (genotype 1) co-infected patients from 16 hospitals in Spain were included. These patients received 4 weeks of PEG-IFN/RBV (lead-in), followed by response-guided therapy with PEG-IFN/RBV plus BOC (a fixed 44 weeks was indicated in the case of cirrhosis). The primary endpoint was the sustained virological response (SVR) rate at 24 weeks post-treatment. Efficacy and safety were evaluated in all patients who received at least one dose of the study drug.

Results: From June 2013 to April 2014, 102 patients were enrolled, 98 of whom received at least one treatment dose. Seventy-three percent were male, 34% were cirrhotic, 23% had IL28b CC, 65% had genotype 1a, and 41% were previous null responders. The overall SVR rate was 67%. Previous null-responders and cirrhotic patients had lower SVR rates (57% and 51%, respectively). Seventy-six patients (78%) completed the therapy scheme; the most common reasons for discontinuation were lack of response at week 12 (12 patients) and adverse events (six patients).

Conclusions: Response-guided therapy with BOC in combination with PEG-IFN/RBV led to an overall SVR rate of 67%, but an SVR rate of only 51% in patients with cirrhosis. The therapy was generally well tolerated. Although the current standards of care do not include BOC + PEG-IFN/RBV, the authors believe

* Corresponding author. Tel.: +34 93 2275574.

E-mail address: rebollar@clinic.cat (M. Martínez-Rebollar).

that this combination can be beneficial in situations where new HCV direct antiviral agent interferon-free therapies are not available yet.

© 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Liver disease caused by chronic hepatitis C virus (HCV) infection is a leading cause of morbidity and mortality among HIV-infected patients in the developed world and represents an important health care problem in this population.^{1,2} HCV genotype 1 is the most prevalent in this population.

The standard treatment for HCV infection until 2009 was the combination of pegylated interferon plus ribavirin (PEG-IFN/RBV) for 48 weeks. However, the sustained virological response (SVR) rate achieved in patients with genotype 1 is low with this combination, at less than 40%.^{3–6} More than half of the patients fail to respond and these patients require retreatment.

In recent years, several drugs with direct antiviral activity against HCV have been developed (direct-acting antivirals, DAAs). The first DAAs used in combination therapy with PEG-IFN/RBV were the protease inhibitors of HCV NS3 telaprevir and boceprevir (BOC). The results of clinical trials with triple therapy in both monoinfected^{7,8} and HIV co-infected patients^{9–11} have been good. However, data on the efficacy of this regimen in patients who have not responded to previous PEG-IFN/RBV therapy are scarce.^{12–17}

Although triple therapy achieves higher rates of SVR than conventional therapies, it may be more toxic and is clearly more expensive. There are data indicating that response-guided therapy (RGT) (32 weeks of triple therapy) in HCV monoinfected patients with previous failure to PEG-IFN/RBV therapy can be as effective as the standard triple therapy (44 weeks), but with lower toxicity and cost.¹⁴

Some studies have evaluated the efficacy and safety of triple therapy with protease inhibitors in HIV–HCV co-infected patients previously treated with PEG-IFN/RBV,^{18,19} and one has evaluated RGT.²⁰

This phase III study assessed the safety and efficacy of RGT with BOC + PEG-IFN/RBV in the retreatment of HIV–HCV genotype 1 patients who were non-responders or relapsers to PEG-IFN/RBV therapy.

2. Methods

2.1. Study design and participating centers

The study was a phase III, prospective, multicenter, open-label, single-arm trial performed in the specialized HIV units of 16 hospitals of Spain. The study was conducted in accordance with the principles of Good Clinical Practice. The institutional ethics committee of Hospital Clinic of Barcelona (coordinating center) and AEMPS (La Agencia Española de Medicamentos y Productos Sanitarios; Spanish drug agency) approved the study, having taken into account the opinions of the other Clinical research ethics committees involved in the project (16 hospitals in Spain). All patients provided written informed consent before entering the study. The clinical trial is registered in EudraCT (number 2012-003984-23). The study design is illustrated in Figure 1.


2.2. Patients

HIV–HCV co-infected patients who had received medical care for their HIV infection at any of the hospitals participating in the study were enrolled from June 2013 to April 2014. The patients had to fulfill the following inclusion criteria: previous non-responders or relapsers to PEG-IFN/RBV therapy; HIV infection with a CD4 cell count >100 cells/mm³ and undetectable plasma HIV viral load (<50 copies/ml) for more than 6 months; the antiretroviral treatment had to contain raltegravir (at least during the last 6 weeks).

Cirrhosis was defined by a liver biopsy showing F4 liver fibrosis, or transient elastography showing a liver stiffness of >12.5 kPa. Exclusion criteria included the following: hepatitis B virus (HBV) infection or any other cause of clinically significant liver disease, decompensated liver disease, a severe psychiatric disorder, and active substance abuse.

2.3. Treatment and monitoring

Pegylated interferon- α 2a was administered subcutaneously at a dose of 180 μ g once weekly. Ribavirin was administered twice a



HCV-VL: Viral load of hepatitis C virus. PR: Peg-Interferon plus Ribavirin; TW8: Therapy Week 8; TW12: Therapy Week 12

Figure 1. Study design (HCV-VL, viral load of hepatitis C virus; PR, pegylated interferon plus ribavirin; TW8, therapy week 8; TW12, therapy week 12).

day at a dose of 800 to 1200 mg per day on the basis of body weight. Boceprevir was administered at a dose of 800 mg three times daily. During the 4-week lead-in period, all patients received PEG-IFN/RBV. Subsequent treatment varied according to the degree of liver fibrosis and viral response at this point: (1) patients with an HCV RNA decrease of $<1 \log_{10}$ and all patients with cirrhosis received BOC + PEG-IFN/RBV for 44 weeks; (2) patients who achieved a $\geq 1 \log_{10}$ drop in HCV RNA received a RGT regimen consisting of (a) BOC + PEG-IFN/RBV for 32 weeks if the HCV RNA level was undetectable at weeks 8 and 12 (completed therapy at week 36); (b) PEG-IFN/RBV for an additional 12 weeks if the HCV RNA level was detectable at week 8 (but undetectable at week 12) (Figure 1).

In all groups, failure to achieve an undetectable HCV RNA level at week 12 resulted in discontinuation of all treatments and advancement to follow-up. Plasma HCV RNA levels were measured using the VERSANT HCV RNA 1.0 Assay (kPCR) (Siemens Healthcare), which has a lower limit of quantification and detection of 15 IU/ml. Measurements were performed at the baseline visit, weeks 4, 8, 12, 24, 36, and 48, as well as at weeks 12 and 24 of the follow-up period.

2.4. Assessment of efficacy

The primary measure of efficacy was the SVR rate, defined as the proportion of patients with undetectable HCV RNA in serum at the end of follow-up (24 weeks after cessation of treatment), by an intent-to-treat (ITT) analysis of the whole population and also according to baseline characteristics. Possible predictors of SVR were also analyzed.

2.5. Assessment of safety

Adverse events were graded according to a modification of the World Health Organization scale. Therapy was permanently discontinued in patients who developed life-threatening events. In the case of hematological toxicity, the RBV or PEG-IFN dose was lowered according to the drug label recommendations, and full doses were restarted, if possible, when the hematological parameters had returned to previously normal levels for that patient. The use of granulocyte colony-stimulating factor (G-CSF) and erythropoietin was permitted in this study and used at the discretion of the physician responsible for each patient.

2.6. Statistical analysis

Analyses of the primary outcome (SVR) included data from all patients who received at least one dose of any study medication. Other efficacy analyses included the proportion of patients with an early response (i.e., undetectable HCV RNA level at weeks 4 and 8) in those who achieved SVR and the proportion of patients with a relapse.

The proportion of patients with SVR was expressed as a percentage with the 95% confidence interval (CI). Quantitative characteristics were described using the mean and standard deviation (SD) or median and interquartile range (IQR) and compared between groups with the *t*-test and Wilcoxon rank sum test, respectively. Qualitative variables were described using the absolute frequency and percentage and were compared between groups with the Chi-square test or Fisher's exact test. Logistic regression models were used to identify baseline factors influencing SVR. Characteristics were chosen on the basis of clinical judgment and statistical criteria (simple regression model *p*-value <0.1) and were evaluated in a stepwise fashion. All tests were two-tailed with the significance level set at 5%. The statistical software used for the analyses was Stata Release 13 (StataCorp LP, College Station, TX, USA).

3. Results

3.1. Baseline characteristics

A total of 102 patients were included in the study, of whom 98 received at least one treatment dose and were included in the analysis (Figure 2). The baseline demographic characteristics are shown in Table 1. The mean age of the patients was 49 years; 100% of the patients were Caucasian and 73% were male.

The prevalence of infection with HCV genotypes 1a and 1b was 65% and 35%, respectively. Polymorphism IL28B CC was present in 23% of patients. A total of 34% of patients had cirrhosis.

Most patients were non-responders to previous HCV therapy: 41% were null responders and 23% were partial responders. One third of patients included were relapsers.

In accordance with the inclusion criteria of the study, all patients had an undetectable HIV viral load and a high CD4 cell count (median 674, IQR 510–946 cells/mm³).

Following the study design, patients were divided into three therapy groups: 48 patients (67% with cirrhosis) entered the long arm (BOC + PEG-IFN/RBV for 48 weeks) and 50 patients entered the RGT arm; the treatment duration could be shortened to 36 weeks in 12 of these latter patients.


3.2. Efficacy

The global SVR rate was 67% (95% CI 57–76%). In particular, the SVR rate was 85% among patients with prior relapse and 57% among those with a previous null response. In cirrhotic patients, the SVR rate dropped to 51% (Table 2).

When an analysis was done by treatment arm, the SVR rate was 48% with the long treatment, 92% with the short RGT, and 84% in the group receiving long RGT.

Viral breakthrough occurred in only four patients. HCV relapsed during follow-up in 10 patients (13% of patients with HCV negative at the end of therapy); in three cases the relapse was delayed, occurring between weeks 12 and 24 of follow-up. Nine relapses occurred in the group of patients assigned to the fixed long arm therapy.

Sixty-nine patients (70%) had a good response to PEG-IFN/RBV, defined as a decrease in HCV RNA of $\geq 1 \log_{10}$ IU/ml after the



*patients with detectable HCV RNA at week 12 of therapy had to discontinue all therapy (futility rule established in the protocol)

Figure 2. Flow chart. *Patients with detectable HCV RNA at week 12 of therapy had to discontinue all therapy (futility rule established in the protocol).

Table 1
Baseline characteristics^a

| Variable | Summary statistics |
|----------------------------------|---|
| Age, years | 49 (SD 6) |
| Sex | Male 72 (73%) Female 26 (27%) Total 98 (100%) |
| IL28 | CC 21 (23%) CT 65 (70%) TT 7 (8%) Total 93 (100%) |
| HCV viral load IU/ml | 2 291 335 (758 209–4 303 728) |
| HCV genotype | 1a 61 (65%) 1b 33 (35%) Total 94 (100%) |
| Previous response to HCV therapy | Breakthrough 6 (7%) Relapse 27 (30%) Null response 37 (41%) Partial response 21 (23%) Total 91 (100%) |
| Degree of liver fibrosis | F1 36 (38%) F2 11 (11%) F3 16 (17%) F4 33 (34%) Total 96 (100%) |
| % CD4 | 37.65 (29–999.9) |
| CD4 count, cells/mm ³ | 674 (510–946) |
| HIV viral load | 25 (19–37) |

IL28, interleukin 28; HCV, hepatitis C virus.

^a Results are reported as the arithmetic mean (standard deviation, SD), number (column percentage), or median (interquartile range).

4-week lead-in period; in the cirrhotic patients this response was worse (20 patients; 61%).

The decrease of 1 log HCV RNA at week 4 was associated with a higher rate of SVR; nevertheless, those patients who did not show a decrease of 1 log HCV RNA during this period had a very low SVR rate (17%). The positive predictive value (PPV) of achieving SVR in the group of patients with a response at 4 weeks was 84%; the PPV was lower in cirrhotic patients (70%).

Similarly, the 8-week response (decrease ≥ 2 log or HCV RNA undetectable at week 8 of therapy) was related to SVR; 66% of

patients who had this response achieved SVR (PPV 73%). Of most importance at this point is the negative predictive value (100%); no patient without a response at 8 weeks achieved SVR.

The simple logistic regression analysis identified three factors that were significantly associated with the achievement of SVR: previous response to PEG-IFN/RBV therapy (no null response vs. null response), 4-week response, and absence of cirrhosis. In this study, no positive relationship was found between SVR and sex, IL28b, or genotype 1 subtype (Table 3).

In the multiple model, the following factors remained independently associated with SVR: a good response at 4 weeks (vs. not presenting such a response, odds ratio (OR) 9.50, 95% CI 3.12–28.95; $p = 0.0001$) and the absence of cirrhosis (vs. cirrhosis, OR 3.22, 95% CI 1.05–9.89; $p = 0.0407$).

3.3. Safety

Seventy-six patients completed the assigned treatment schedule. Twelve patients discontinued treatment at week 12 of therapy due to the futility rule established in the protocol; this represents 55% of patients who prematurely stopped the therapy. The second reason for ending the study drugs was toxicity (six patients). Two other patients discontinued at weeks 8 and 12 of their own volition. One patient stopped after receiving a diagnosis of metastatic hepatocellular carcinoma and one patient was lost at week 36 of follow-up.

Adverse events (AEs) were very frequent; 93% of patients presented at least one AE, but the mean was seven AEs per patient. Most AEs were mild and known to be related to PEG-IFN/RBV and BOC therapy (flu-like symptoms, asthenia, neuropsychiatric symptoms, hematological toxicity, dysgeusia, and rash).

Due to hematological toxicity, the dose of RBV was decreased in 45% of patients and the dose of PEG-IFN was decreased in 23% of patients. No difference in the SVR rate was seen between patients who completed the whole therapy and those who needed a dose modification. Overall, 20% of patients required treatment with erythropoietin and 14% with G-CSF; two patients received transfusions. Regarding the degree of liver fibrosis, no more AEs were observed in cirrhotic patients; however, the need to reduce the dose of PEG-IFN and to use erythropoietin or drugs to treat dermatological toxicities was significantly greater in these patients.

Twenty-seven serious AEs (SAEs) were reported in 19 patients; these led to therapy discontinuation in six patients. The most frequent SAEs were hematological (thrombocytopenia, $n = 5$; neutropenia, $n = 8$; anemia, $n = 3$). SAEs were most frequent in patients with cirrhosis (30% vs. 13%, $p = 0.0358$).

4. Discussion

This appears to be the first phase III trial with BOC in HIV-HCV co-infected patients. The results of this study showed that RGT with BOC plus PEG-IFN/RBV achieved high rates of SVR in patients with a prior treatment failure. This was most evident in patients who had previously relapsed or had a breakthrough to PEG-IFN/RBV, who showed a SVR rate of up to 80%. On the other hand, the response was moderate in previously null responders. These results are in line with those reported in recent studies on the retreatment of HCV monoinfected patients,¹⁴ and in series in co-infected patients.¹⁸

Data on RGT to re-treat HCV in HIV co-infected patients are scarce. A recent study in 21 patients showed good results with this strategy,²⁰ although most of the patients were treatment-naïve (71%) and no prior partial or null responders were included in that study, unlike the present one.

Table 2
Sustained virological response (SVR) rate according to baseline characteristics and HCV RNA evolution during treatment

| Variable | SVR, n (%) | p-Value |
|---|---|----------------------|
| Sex | Male 47 (65) Female 19 (73) | 0.4673 ^a |
| IL28 | CC 14 (67) CT 45 (69) TT 2 (28) | 0.1291 ^b |
| HCV genotype | 1a 40 (65) 1b 24 (72) | 0.4776 ^a |
| Previous response to PEG-IFN/RBV therapy | Breakthrough 5 (83) Relapse 23 (85) Partial response 14 (66) Null response 21 (57) | 0.0842 ^b |
| Previous null response | No 42 (73) Yes 21 (57) | 0.0328 ^a |
| Cirrhosis | No 48 (76) Yes 18 (51) | 0.0141 ^b |
| Response at 4 weeks (HCV RNA decrease ≥ 1 log) | No 10 (17) Yes 56 (81) | <0.0001 ^a |
| Response at 8 weeks (HCV RNA undetectable or decrease ≥ 2 log) | No 0 (0) Yes 66 (72) | 0.0002 ^b |
| Early response (HCV RNA undetectable at weeks 8 and 12) | No 56 (64) Yes 10 (91) | 0.0964 ^b |

IL28, interleukin 28; HCV, hepatitis C virus; PEG-IFN/RBV, pegylated interferon/ribavirin.

^a Chi-square test.

^b Fisher's exact test.

Table 3
Variables related to a sustained virological response (SVR)

| Variable | | Crude OR | (95% CI) | p-Value (simple model) | Adjusted OR | (95% CI) | p-Value (multiple model) |
|------------------------------------|--------|----------|--------------|------------------------|-------------|--------------|--------------------------|
| Sex (n = 83) | Female | 1 | | 0.9138 | | | |
| | Male | 0.94 | (0.33–2.68) | | | | |
| IL28 (n = 79) | CC | 1 | | 0.2235 | | | |
| | CT | 1.22 | (0.39–3.81) | | | | |
| HCV genotype (n = 80) | TT | 0.25 | (0.04–1.77) | | | | |
| | 1a | 1 | | 0.7226 | | | |
| Cirrhosis (n = 83) | 1b | 1.20 | (0.44–3.28) | | | | |
| | No | 2.19 | (1.38–3.49) | 0.0106 | 3.22 | (1.05–9.89) | 0.0407 |
| Previous null response (n = 83) | Yes | 1 | | | 1 | | |
| | No | 1 | | 0.0266 | | | |
| Early response (n = 83) | Yes | 0.34 | (0.13–0.88) | | | | |
| | No | 1 | | 0.1964 | | | |
| Response at 4 weeks (n = 83) | Yes | 4.08 | (0.48–34.48) | | | | |
| | No | 1 | | <0.0001 | 1 | | 0.0001 |
| Response at 8 weeks (n = 78) | Yes | 10.07 | (3.43–29.57) | | 9.50 | (3.12–28.95) | |
| | No | 1 | | - | | | |
| | Yes | 1.00 | - | | | | |

OR, odds ratio; CI, confidence interval; IL28, interleukin 28; HCV, hepatitis C virus.

In agreement with other studies,^{7,14,16,17,21,22} the 4-week response was the best marker to determine the likelihood of SVR. Also, the lack of an 8-week response identified patients who did not benefit from this treatment, and allowed therapy discontinuation at this point. If the predictive value of this marker is confirmed in other studies, it could eventually change the futility rule from 12 weeks to 8 weeks.

It is important to emphasize that only one patient relapsed in the short arm of RGT, showing that a shortened treatment duration in patients with a good initial response is safe and effective.

Patients with advanced liver disease, who usually have a mild response,^{23–25} also achieved a satisfactory rate of SVR.

Although the safety profile was poor and a high number of AEs were reported, all of them have been described previously,^{7,14,16,23,26} most were mild, and only six patients discontinued treatment for this reason. Cirrhotic patients did not report more AEs or interruptions of therapy compared to non-cirrhotic patients in this study, unlike those published by other authors.^{24,25} However, cirrhotic patients in the present study had more SAEs and required more drug dose modifications and use of adjuvant therapy. Therefore, these patients should be followed closely to complete the therapy scheme and achieve a good response.

By trial design, SVR was determined at 24 weeks after the end of therapy. In fact three patients relapsed after 12 weeks of follow-up, which shows that according to this approach, the determination of SVR at 24 weeks may be more useful than at 12 weeks.

The most important limitation of this study is the lack of a control group. Phase III studies are often randomized with a group receiving the standard treatment; however, very difficult to treat HIV–HCV co-infected patients were included, for whom treatment options are limited. In this population, the use of a control group would have been difficult to justify from an ethical point of view because response rates to the PEG–IFN/RBV scheme are low. Finally, it is agreed that with the advent of interferon-free therapy, the treatment regimen evaluated herein has been rendered obsolete. However, these newer drugs are not available for all patients. Based on the high efficacy obtained in this study, especially in prior relapsers, it is believed that the scheme of RGT with BOC + PEG–IFN/RBV is a good therapeutic and cost-effective alternative in countries where new antiviral HCV drugs are not available.

In conclusion, response-guided therapy with boceprevir in combination with PEG–IFN/RBV leads to adequate SVR rates in HCV genotype 1 patients who are previous non-responders or relapsers to PEG–IFN/RBV therapy. The therapy was generally well tolerated.

Acknowledgements

On behalf of the Spanish BOC HIV–HCV Study Group: M. Laguno, M. Martínez-Rebollar, A. Cruceta, E. de Lazzari, and J. Mallolas from Hospital Clínic de Barcelona/IDIBAPS, Barcelona, Spain; M.A. Von Wichmann from Hospital Universitario de Donostia, Donostia, Spain; E. Van den Eynde and D. Podzamczar from Hospital Universitari de Bellvitge, Bellvitge, Spain; J. Navarro and M. Crespo from Hospital Universitari Vall d'Hebrón, Barcelona, Spain; C. Cifuentes from Hospital Son Llàtzer, Palma de Mallorca, Spain; J. Murillas from Hospital Son Espases, Palma de Mallorca, Spain; S. Veloso and F. Vidal from Hospital Universitari Joan XXIII, Tarragona, Spain; J.M. Guardiola from Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; A. Jou and C. Tural from Hospital Universitari Germans Trias i Pujol, Badalona, Spain; J.L. Gómez-Sirvent from Hospital Universitario de Canarias, Tenerife, Spain; M. Cervantes from Corporació Sanitària Parc Taulí, Sabadell, Spain; J.A. Pineda from Hospital Universitario de Valme, Seville, Spain; S. López-Calvo from Hospital Universitario A Coruña, La Coruña, Spain; A. Carrero and J. Berenguer from Hospital Universitario Gregorio Marañón, Madrid, Spain; M.L. Montes and J. González from Hospital Universitario de La Paz, Madrid, Spain; E. Deig from Hospital de Granollers, Granollers, Spain; A. Tapiz and A. Flor from Fundació Althaia, Manresa, Spain; J.D. Ruiz-Mesa and M. Delgado from Hospital Regional, Malaga, Spain.

Funding: Funded by Merck: BOC–HIV Study. Maria Martínez-Rebollar is funded by a grant Sara Borrell, CM13-00123, from *Instituto de Salud Carlos III, Ministerio Economía y Competitividad*. Other authors declare no other conflict of interest.

References

- Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. *Ann Intern Med* 2003;**138**:197–207.
- Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. *N Engl J Med* 1998;**338**:853–60. <http://dx.doi.org/10.1056/NEJM199803263381301>
- Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. *N Engl J Med* 2004;**351**:438–50.
- Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. *JAMA* 2004;**292**:2839–48.
- Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. *N Engl J Med* 2004;**351**:451–9.

6. Laguno M, Murillas J, Blanco JL, Martínez E, Miquel R, Sánchez-Tapias JM, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. *AIDS* 2004;**18**: F27–36.
7. Poordad F, McCone Jr J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. *N Engl J Med* 2011;**364**(13):1195–206. <http://dx.doi.org/10.1056/NEJMoa1010494>
8. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. ADVANCE Study. Telaprevir for previously untreated chronic hepatitis C virus infection. *N Engl J Med* 2011;**364**:2405–16. <http://dx.doi.org/10.1056/NEJMoa1012912>
9. Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. *Lancet Infect Dis* 2013;**13**:597–605. [http://dx.doi.org/10.1016/S1473-3099\(13\)70149-X](http://dx.doi.org/10.1016/S1473-3099(13)70149-X)
10. Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. *Ann Intern Med* 2013;**159**:86–96. <http://dx.doi.org/10.7326/0003-4819-159-2-201307160-00654>
11. Mandorfer M, Payer BA, Niederecker A, Lang G, Aichelburg MC, Strassl R, et al. Therapeutic potential of and treatment with boceprevir/telaprevir-based triple-therapy in HIV/chronic hepatitis C co-infected patients in a real-world setting. *AIDS Patient Care STDS* 2014;**28**:221–7. <http://dx.doi.org/10.1089/apc.2013.0359>
12. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. *N Engl J Med* 2011;**364**:2417–28. <http://dx.doi.org/10.1056/NEJMoa1013086>
13. Montes ML, Nelson M, Girard PM, Sasadeusz J, Horban A, Grinsztejn B, et al. Telaprevir-based therapy in patients coinfecting with chronic hepatitis C virus infection and HIV: INSIGHT study. *J Antimicrob Chemother* 2016;**71**:244–50. <http://dx.doi.org/10.1093/jac/dkv323>
14. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. *N Engl J Med* 2011;**364**:1207. <http://dx.doi.org/10.1056/nejmoa1009482>
15. Asselah T. Triple therapy with boceprevir or telaprevir for prior HCV non-responders. *Best Pract Res Clin Gastroenterol* 2012;**26**:455–62. <http://dx.doi.org/10.1016/j.bpg.2012.09.003>
16. Flamm SL, Lawitz E, Jacobson I, Bourlière M, Hezode C, Vierling JM, et al. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. *Clin Gastroenterol Hepatol* 2013;**11**. <http://dx.doi.org/10.1016/j.cgh.2012.10.006>. 81–7.e4; quiz e5.
17. Vierling JM, Davis M, Flamm S, Gordon SC, Lawitz E, Yoshida EM, et al. Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. *J Hepatol* 2014;**60**:748–56. <http://dx.doi.org/10.1016/j.jhep.2013.12.013>
18. Neukam K, Munteanu DI, Rivero-Juárez A, Lutz T, Fehr J, Mandorfer M, et al. Boceprevir or telaprevir based triple therapy against chronic hepatitis C in HIV coinfection: real-life safety and efficacy. *PLoS One* 2015;**10**:e0125080. <http://dx.doi.org/10.1371/journal.pone.0125080>
19. Cotte L, Braun J, Lascoux-Combe C, Vincent C, Valantin MA, Sogni P, et al. Telaprevir for HIV/hepatitis C virus-coinfecting patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 Telaprevir): an open-label, single-arm, phase 2 trial. *Clin Infect Dis* 2014;**59**:1768–76. <http://dx.doi.org/10.1093/cid/ciu659>
20. Mandorfer M, Steiner S, Schwabl P, Payer BA, Aichelburg MC, Lang G, et al. Response-guided boceprevir-based triple therapy in HIV/HCV-coinfecting patients: the HIVCOBOC-RGT study. *J Infect Dis* 2015;**211**:729–35. <http://dx.doi.org/10.1093/infdis/jiu516>
21. Salmon D, Bani-Sadr F, Gilbert C, Rosenthal E, Valantin MA, Simon A, et al. HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients. *J Clin Virol* 2015;**73**:32–5. <http://dx.doi.org/10.1016/j.jcv.2015.10.010>
22. Poordad F, Bronowicki J, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. *Gastroenterology* 2012;**143**. <http://dx.doi.org/10.1053/j.gastro.2012.05.011>. 608–18.e5.
23. Bruno S, Vierling JM, Esteban R, Nyberg LM, Tanno H, Goodman Z, et al. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. *J Hepatol* 2013;**58**:479–87.
24. Hézode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)–NCT01514890. *J Hepatol* 2013;**59**:434–41. <http://dx.doi.org/10.1016/j.jhep.2013.04.035>
25. Miaillhes P, Gilbert C, Lacombe K, Arends JE, Puoti M, Rockstroh JK, et al. Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfecting patients. *Liver Int* 2015;**35**:2090–9. <http://dx.doi.org/10.1111/liv.12799>
26. Manns MP, McCone J, Davis MN, Rossaro L, Schiff E, Shiffman ML, et al. Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials. *Liver Int* 2014;**34**:707–19. <http://dx.doi.org/10.1111/liv.12300>